DEF: Agape ATP Seeks Shareholder Approval for Reverse Split, $300M Capital Raise

Sentiment:

Proxy Statement for Annual Meeting 9 January 2026 6:10 AM

Agape ATP Corporation will hold its Annual Meeting on January 30, 2026, seeking shareholder approval for a significant capital raise, a reverse stock split, and an increase in authorized shares to support future growth and strategic initiatives.

Capital raiseThe company is seeking stockholder approval for the potential issuance of shares of common stock up to an aggregate offering price of $300,000,000.This capital raise would be conducted pursuant to a registration statement on Form S-3 (S-3 Shelf) that the company intends to file.The primary purpose of this capital raise is to provide a reliable source of capital for working capital and general corporate purposes.The issuance of these shares will have a dilutive effect on the existing stockholders, impacting their voting power and economic rights.

Worse than expectedThe proposal for a reverse stock split of up to 1:5000 is often indicative of a low stock price and efforts to maintain listing requirements, which is generally perceived negatively by the market.The request to increase authorized common stock from 500 million to 30 billion shares, a 60-fold increase, signals a potential for massive future dilution that could significantly devalue existing shareholder equity.The approval for a $300 million S-3 Shelf offering, combined with the other proposals, suggests a substantial need for capital that will likely result in significant dilution for current shareholders.

Summary

The Annual Meeting of Stockholders will be held virtually on January 30, 2026, at 10:00 p.m. Malaysia Time (10:00 a.m. Eastern Time).
Stockholders will vote on ratifying the appointment of Assentsure PAC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Five directors are proposed for re-election: How Kok Choong, Wilfredo Fernando Cortizo, Ramesh Ruben Louis, Ni Luh Dharma Kerti Natih, and Rose Marie Kadende Kaiser.
Shareholder approval is sought for the potential issuance of common stock up to an aggregate offering price of $300,000,000, pursuant to an S-3 Shelf registration, to comply with Nasdaq Listing Rule 5635(d).
An amendment to the Articles of Incorporation is proposed to effect one or more reverse stock splits of up to one-for-five thousand (1:5000).
Another amendment is proposed to increase the number of authorized shares of common stock from 500,000,000 to 30,000,000,000.
The Board of Directors unanimously recommends voting FOR all proposals.

Sentiment

Score: 3

Explanation: The proposals for a reverse stock split, a substantial increase in authorized shares, and a large potential capital raise, while framed as strategic, typically signal significant future dilution and potential underlying stock price issues, leading to a negative market perception. These actions often indicate a company is addressing challenges rather than reporting strong performance.

Positives

The potential $300,000,000 capital raise is intended to provide a reliable source of capital for working capital and general corporate purposes.
Increasing authorized shares provides flexibility for future financing transactions, contemplated staffing acquisitions, equity incentives for employees, and strategic relationships.
The Board has established robust corporate governance structures, including independent directors and dedicated Audit, Compensation, and Nominating/Corporate Governance Committees.
The company has adopted a Code of Ethical Business Conduct and a clawback policy for erroneously awarded compensation.

Negatives

The proposed potential issuance of shares up to $300,000,000 will have a dilutive effect on the existing stockholders, impacting their voting power and economic rights.
The proposed increase in authorized common stock from 500,000,000 to 30,000,000,000 shares (a 60-fold increase) signals a potential for massive future dilution.
A reverse stock split, while intended to increase market price and attract institutional investors, often signals a low stock price and can be perceived negatively by the market, and may not result in a proportional or permanent price increase.

Risks

The reverse stock split may not increase the market price of common stock in proportion to the reduction in outstanding shares or result in a permanent price increase.
The increase in authorized but unissued shares could, under certain circumstances, have an anti-takeover effect, potentially limiting shareholders' opportunities to dispose of shares at higher prices during takeover attempts.
Future issuances of the significantly increased authorized shares could have a dilutive effect on earnings per share, book value per share, voting power, and percentage interest of current shareholders.
Failure to obtain stockholder approval for the stock issuance proposal would prevent the company from issuing shares in excess of the Nasdaq 20% Rule cap if sold at a price less than the Minimum Price.

Future Outlook

The company expects to continue needing additional external financing for working capital and strategic initiatives, including contemplated staffing acquisitions and attracting/retaining top talent. The proposed increase in authorized shares aims to provide maximum flexibility for future financing transactions, equity incentives, strategic relationships, and business expansion without requiring further stockholder approval for each instance.

Management Comments

"The Board of Directors would effect one or more reverse splits with the primary intent of increasing the market price of our common stock to make it more attractive to a broader range of institutional and other investors."
"The Board of Directors believes that an increased stock price may encourage investor interest and improve the marketability of our common stock to a broader range of investors, and thus enhance liquidity."
"Our Board has determined that the potential issuance of shares of the Company's Common Stock, having an aggregate offering price of up to $300,000,000 pursuant to a S-3 Shelf is in the best interests of the Company and its stockholders for purposes of providing a reliable source of capital for working capital and general corporate purposes."
"The Company expects to continue to need additional external financing to provide additional working capital and fund strategic initiatives. This includes providing financial resources for contemplated staffing acquisitions, enabling the Company to attract and retain top talent while enhancing operational capabilities."

Industry Context

The company's CEO has over 20 years of experience in senior management roles within the health and wellness industry. The pursuit of a significant capital raise and increased share authorization, partly for 'contemplated staffing acquisitions,' suggests a strategy to expand operational capabilities, potentially within or adjacent to its core health and wellness business. The proposals are aimed at enhancing financial flexibility and market appeal, which are common objectives for companies seeking growth and stability in competitive sectors.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer, President, Director, Chairman of the Board of Directors	NA	How Kok Choong	NA	Proposed for re-election to serve until the next Annual Meeting or until successors are elected.
Director	NA	Wilfredo Fernando Cortizo	NA	Proposed for re-election to serve until the next Annual Meeting or until successors are elected.
Independent Director	NA	Ramesh Ruben Louis	NA	Proposed for re-election to serve until the next Annual Meeting or until successors are elected.
Independent Director	NA	Ni Luh Dharma Kerti Natih	NA	Proposed for re-election to serve until the next Annual Meeting or until successors are elected.
Independent Director	NA	Rose Marie Kadende Kaiser	NA	Proposed for re-election to serve until the next Annual Meeting or until successors are elected.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Auditor Ratification	Stockholders are asked to ratify the appointment of Assentsure PAC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Assentsure PAC was appointed on April 29, 2024, replacing Marcum Asia CPAs LLP.	2025-12-31	Ensures continued independent oversight of financial statements and compliance with regulatory requirements.
Board Composition	The Board consists of five members, with three independent directors (Ramesh Ruben Louis, Ni Luh Dharma Kerti Natih, Rose Marie Kadende Kaiser) meeting Nasdaq independence requirements.	NA	Maintains compliance with Nasdaq listing standards and promotes independent oversight of management.
Board Committees	The Board has an Audit Committee (Chair: Ramesh Ruben Louis, designated financial expert), a Compensation Committee (Chair: Rose Marie Kadende Kaiser), and a Nominating and Corporate Governance Committee (Chair: Ni Luh Dharma Kerti Natih).	NA	Provides specialized oversight for financial reporting, executive compensation, and corporate governance matters, enhancing accountability.
Code of Ethics	The company has adopted a Code of Ethical Business Conduct.	NA	Establishes clear ethical standards for all employees and directors, promoting integrity and compliance.
Clawback Policy	The company has adopted a clawback policy in connection with the recovery of erroneously awarded compensation.	NA	Aligns executive compensation with performance and accountability, allowing recovery of compensation if financial results are restated due to misconduct.
Board Leadership Structure	The positions of Chairman and Chief Executive Officer are combined, held by Dr. How Kok Choong.	NA	Allows for unified leadership and efficient communication between management and the Board, though it may reduce independent oversight compared to a split role.

Related Party Transactions

Amounts due from related parties: TH3 Holdings Sdn Bhd ($2,706 as of June 30, 2025; $1,582 as of Dec 31, 2024) for prepayment of IT expenses, and ATPC Lega Global Sdn Bhd ($730 as of June 30, 2025 and Dec 31, 2024) for general expenses payment on behalf.
Accounts payable to related parties: CTA Nutriceuticals (Asia) Sdn Bhd ($29,755 as of June 30, 2025; $30,554 as of Dec 31, 2024) for product purchases, SY Welltech Sdn Bhd ($38 as of June 30, 2025; $71 as of Dec 31, 2024) for beauty product purchases, and Cedar Wellness Sdn Bhd ($1,656 as of June 30, 2025) for skin care and healthcare product purchases.
Other payables to related parties: CTA Nutriceuticals (Asia) Sdn Bhd ($144 as of June 30, 2025; $494 as of Dec 31, 2024) for general product purchases, Cedar Wellness Sdn Bhd ($5,772 as of June 30, 2025) for selling and event related expenses, Ms. Low Mui Chin ($1,227 as of June 30, 2025) for selling and event related expenses, and Mr. How Kok Choong ($230,249 as of June 30, 2025; $356 as of Dec 31, 2024) for salary, commission expense, and borrowing from director.
Purchases of products for complementary health therapies from CTA Nutriceuticals (Asia) Sdn Bhd: $86,199 (Q2 2025), $80,504 (Q2 2024), $172,026 (H1 2025), $161,807 (H1 2024), $335,494 (FY 2024), $272,993 (FY 2023).
Purchases of beauty products from SY Welltech Sdn Bhd: $96 (Q2 2025), $819 (Q2 2024), $150 (H1 2025), $16,624 (H1 2024), $17,600 (FY 2024), $18,516 (FY 2023).
Purchases of skin care and healthcare products from Cedar Wellness Sdn Bhd: $10,000 (Q2 2025 and H1 2025).
Commission expense paid to Mr. How Kok Choong: $372 (Q2 2025), $619 (Q2 2024), $766 (H1 2025), $1,351 (H1 2024), $3,012 (FY 2024), $5,947 (FY 2023).
Rental income from Ando Design Sdn Bhd: $230 (H1 2025), $1,268 (H1 2024), $2,630 (FY 2024 and FY 2023).
Rental income from TH3 Holdings Sdn Bhd: $207 (Q2 2025), $190 (Q2 2024), $414 (H1 2025), $380 (H1 2024), $789 (FY 2024), $460 (FY 2023).
IT support services fee to TH3 Holdings Sdn Bhd: $15,271 (Q2 2025), $14,574 (Q2 2024), $30,421 (H1 2025), $28,666 (H1 2024), $59,371 (FY 2024), $54,956 (FY 2023).
Office rental expense to DSY Wellness and Longevity Center Sdn Bhd: $27,629 (Q2 2025), $7,606 (Q2 2024), $55,258 (H1 2025), $15,213 (H1 2024), $55,239 (FY 2024), $31,563 (FY 2023).

Stakeholder Impact

Shareholders: Face potential significant dilution of their ownership, voting power, and economic rights due to the proposed $300 million stock issuance and the massive increase in authorized shares. The reverse stock split aims to increase per-share price but may not guarantee long-term value or liquidity.
Employees/Management: The increase in authorized shares provides flexibility for equity-based compensation, potentially aiding in attracting and retaining top talent. Executive compensation details are provided for the CEO and CFO.
Customers/Suppliers: No direct impact is explicitly mentioned, but a successful capital raise could strengthen the company's financial position, potentially supporting business operations and product development.
Creditors: A stronger capital base from the potential raise could improve the company's financial stability, which may be viewed positively by creditors.

Next Steps

Hold the Annual Meeting of Stockholders on January 30, 2026, to vote on the proposed resolutions.
If approved, the Board of Directors will determine the timing and exact ratio for any reverse stock split and file the necessary amendment to the Articles of Incorporation.
If approved, the Board will cause the amendment to increase authorized shares to be implemented by filing with the Secretary of State of Nevada.
If approved, the company intends to file a registration statement on Form S-3 with the SEC for the potential $300,000,000 stock issuance.

Key Dates

Date	Description
2024-04-25	Board of Directors released Marcum Asia CPAs LLP as the company's independent registered public accounting firm.
2024-04-29	Board of Directors appointed Assentsure PAC as the independent registered public accounting firm.
2025-11-04	Record Date for stockholders entitled to notice of, and to vote at, the Annual Meeting.
2026-01-09	Notice and Proxy Statement first sent or given to stockholders of record.
2026-01-30	Annual Meeting of Stockholders held virtually.
2026-09-11	Start of the Notice Period for proxy solicitation in support of director nominees for the 2026 annual meeting.
2026-10-11	End of the Notice Period for proxy solicitation in support of director nominees for the 2026 annual meeting.
2026-11-25	Deadline for stockholder proposals (outside Rule 14a-8) for presentation at the 2026 annual meeting.

Recommendation

sell

The combination of a proposed reverse stock split (up to 1:5000), a massive increase in authorized shares (from 500 million to 30 billion), and a significant potential capital raise ($300 million S-3 Shelf) strongly suggests the company is facing challenges, likely related to its stock price and need for substantial funding. While framed as strategic, these actions typically lead to significant dilution for existing shareholders and often indicate underlying operational or financial weaknesses. A reverse split is frequently a measure to avoid delisting, and a vast increase in authorized shares paves the way for future capital raises that will further dilute ownership. These factors present a high risk profile for current investors, making a 'sell' recommendation appropriate.

Keywords

SEC filing, Proxy Statement, Annual Meeting, Stock Split, Capital Raise, Share Dilution, Corporate Governance, Nasdaq Listing, Agape ATP Corporation, ATPC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.